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Objectives: Studies regarding the role of gamma aminobutyric acid (GABA) in depression are conflicting.
Therefore, it was decided to examine the effect of different drugs that enhance the GABA system on the time
of immobility induced by the forced swim test (FST).
Materials and methods: Adult albino mice were divided into several groups of six animals. Each group
received an intraperitoneal injection of either imipramine (10, 20, or 30 mg/kg), diazepam (0.5, 1, or 2 mg/kg),
vigabatrin (100, 200, or 300 mg/kg), zolpidem (2.5, 5, or 10 mg/kg), or alprazolam (1, 2.5, or 5 mg/kg).
Control groups received the appropriate vehicle. One hour after injection, the duration of immobility was
measured for 5 min in the FST. The percentage change in the duration of immobility from the control
was calculated for each group. The statistical test of the difference between the treated and the control groups
was calculated using unpaired Student’s t-test.
Results: Imipramine produced a significant dose-dependent decrease in the duration of immobility (78, 74,
and 56%, respectively). Different doses of diazepam, vigabatrin, and zolpidem produced a significant increase
in the duration of immobility (119, 126, and 128%), (116, 124, and 128%), and (108, 109, and 119%),
respectively. The two low doses of alprazolam produced a significant increase (115 and 120%), while the high
dose produced a significant decrease in the duration of immobility (74%).
Conclusion: Increasing central GABAergic activity by different mechanisms has resulted in a depressant-like
activity measured as an increase in the duration of immobility in the FST model of depression.
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D
epression is a common mental disorder affecting
millions of people worldwide and is also a lead-
ing cause of disability. At its worst, depression
can lead to suicide, a fact associated with the loss of
about 850,000 lives every year (1).
Many neurotransmitters have been suggested to be
involved in the mechanisms of depression and antidepres-
sant drugs. A strong role for the monoamines, serotonin
(5-hydroxytryptamine, 5-HT) and noradrenaline (NA) in
major depression has been proposed (2). On the other
hand, the role of gamma aminobutyric acid (GABA) is
still not well recognized and several studies are showing
conflicting findings regarding any crucial role for GABA
in the pathophysiology of depression. It was reported
that small doses of GABA or its agonists (muscimol,
baclofen, sodium valproate, piracetam, and fengabine)
decreased a forced swimming-induced immobility period,
while higher doses enhanced the immobility period (3).
Conversely, diazepam, flurazepam, pentobarbital, and
phenobarbital enhanced the immobile behavior in a
dose-dependent manner (4). Clinically, it has been sug-
gested that reduced concentrations of GABA and altered
expression of GABAA receptors are common abnormal-
ities observed in major depressive disorders (5). However,
currently available GABA potentiating drugs are ineffec-
tive as antidepressants (5). On the basis of these findings,
it was decided to examine if enhancing central GABA
by different mechanisms has a direct role in an estab-
lished model of animal depression, the forced swim test
(FST). Vigabatrin acts as an irreversible inhibitor for the
enzyme GABA-Transaminase (GABA-T) responsible for
GABA metabolism, which would lead to an increase in
brain GABA levels (6). Diazepam (7) and alprazolam (8)
are positive allosteric modulators of a1-, a2-, a3-, and a5-
containing GABAA receptor subunits, potentiating GABA-
mediated chloride conductance, enhancing GABA-mediated
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inhibitory synaptic events. Zolpidem is a selective agonist for
the a1-subunit of GABAA receptors (9). Imipramine, which
acts by inhibiting the neuronal re-uptake of NA and
serotonin, is included as a standard antidepressant drug
(2). The effect of different doses of these drugs on the
duration of immobility in the FST using albino mice is
reported in this article.
Materials and Methods
Animals
Adult male albino mice weighing 2540 g at the time of
testing were used. The animals were obtained from the
animal house of the Faculty of Pharmacy, Tripoli Uni-
versity, 1 week before the experiment. They were housed
in cages of six each and allowed free access to standard
rodent food pellets and water. The animals were kept at
constant room temperature (20258C), and 12 h dark/
light cycle. All experiments were conducted between
10 am and 12:00 pm. Each experimental group consisted
of six animals per dose and each animal was used only
once. The ethical committee of the Faculty of Pharmacy,
Tripoli University, approved the experimental protocol.
Drugs
Imipramine ampoules (from Polfa, Poland) were diluted
with normal saline. Vigabatrin oral powder (Aventis,
France) was prepared in normal saline. Diazepam (Roch,
Switzerland), alprazolam (Sigma-Aldrich), and zolpidem
(Sigma-Aldrich) were suspended in 1% Tween 80 in saline
solution.
Treatments
The animals were divided into several groups of six
animals each. Each mouse received an intraperitoneal
injection of either imipramine (10, 20, or 30 mg/kg),
diazepam (0.5, 1, or 2 mg/kg), vigabatrin (100, 200, or 300
mg/kg), zolpidem (2.5, 5, or 10 mg/kg), or alprazolam (1,
2.5 or 5 mg/kg) in a volume of 5 ml/kg 60 min prior to the
FST. Control group was given the corresponding vehicle.
Forced swim test
The FST procedure was essentially similar to that de-
scribed by Porsolt et al. (10). The test was modified by
using a Plexiglas cylinder of larger diameter (height 40 cm;
diameter 20 cm) as this was reported to increase the
predictive validity of the mouse FST (11). The depth of
the water in the cylinder was kept at 15 cm above the
bottom of the cylinder so that the animal was forced to
either swim or float without its hind limbs or tail touching
the bottom.
Each mouse was placed inside the cylinder containing
water maintained at 22258C and the duration of im-
mobility was measured for 5 min. The water was replaced
between each test. The mouse was judged to be immobile
whenever it remained floating passively in water making
only those movements necessary to keep its head just
above the water surface (11). The duration of immobility
was measured manually using a stopwatch.
Data presentation and statistical analysis
The mean duration of immobility was calculated for
each group in seconds9standard error. The percentage
changes from the correspondent control (vehicle treated)
group were also calculated. Data generated from the
above studies were statistically analyzed with Excel soft-
ware. Unpaired Student’s t-test (two samples assuming
equal variances) was used to determine the difference
between the treated group and the control group that
received the vehicle. A P value of B0.05 was considered
statistically significant.
Results
Figure 1 shows the effect of the selected drugs on the
duration of immobility in FST. Imipramine produced a
significant dose-dependent reduction in the duration of
immobility with a maximum reduction of 56.3% from the
control group. Ascending doses of diazepam, vigabatrin,
and zolpidem produced a significant increase in the
duration of immobility with a maximum increase of
128, 128.5, and 119.3% from the corresponding control
groups, respectively. On the contrary, alprazolam pro-
duced a dual effect on the duration of immobility, where
the low doses produced a statistically significant increase
in the duration of immobility with a maximum of 120%
from the control group, while the highest dose produced a
statistically significant reduction in the duration of
immobility (74.9% from the control group).
Discussion
The current study uses a well-established model of animal
depression in order to examine if the selected drugs that
act through the GABA system have any antidepressant-
like activity.
Consistent with many previous findings, imipramine
produced a significant dose-dependent antidepressant-
like effect in the mouse FST. The antidepressant action of
imipramine is thought to be due to reuptake inhibition of
the monoamines serotonin and NA (2). Imipramine has
also been suggested to produce its antidepressant action
through the interference with the GABAergic system,
where the antidepressant effect of imipramine was en-
hanced by picrotoxin (GABAA receptor antagonist),
suggesting a possible role for GABA in the antidepressant
effect of imipramine (12).
Except for the high dose of alprazolam, it was found
that all of the selected drugs that enhance central GABA
activity produced a significant increase in the duration of
immobility in FST (i.e. depressant-like action). These
results are in a good agreement with those reported by
Nagatani et al. (4), but contradictory to the proposal
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suggested by Luscher et al. (5). The obtained results can
be explained on the basis of the complexity of GABAA
receptors and its relationship to the monoamines.
GABAA receptors are formed as pentameric combina-
tions of homologous subunits (a16, b13, g13, d, o, u,
p, r13), with receptors formed by a, b and g subunits
being the most common. The a subunits provide the
largest diversity where GABAA receptors are most
frequently classified by their a subunits (13). Each of
these subunits was suggested to be related to certain
function and therapeutic applications. It was reported
that modulators of a2/a3 GABAA receptors subunits,
such as TPA023, had shown clinical proof as novel
anxiolytics and antidepressants (14). The a5-subunit of
the GABAA receptors has been suggested to represent the
‘cognition’ subtype based upon the preferential localiza-
tion of these receptors within the hippocampus and
the well-established role of the hippocampus in learn-
ing and memory (15). The function of a2-containing
GABAA receptors was also suggested to be involved in
antidepressant-like properties (16). From these reported
actions of the GABA subunits, it is therefore logical to
speculate that the depressant-like activity of the drugs
used in the present study might have resulted from the
stimulation of the a1 subunit of the GABAA receptors
either selectively (like zolpedim) or non-selectively (like
diazepam). This would explain the depressant-like action
of all the GABAmimetics used in this study.
The dual action induced by alprazolam is more
intricate to explain. However, at the small doses, alpraz-
olam might have acted as a full agonist at all subunits of
the GABAA receptors especially the a1-subunit enhan-
cing GABA mediated inhibitory effect, thus prolonging
the duration of immobility in the FST. Conversely, the
high dose of alprazolam might have acted as an agonist
on the a2 adrenergic auto-receptors resulting in an
enhancement of 5-HT release, producing an antidepres-
sant effect in the FST. This suggestion is supported by the
findings that alprazolam’s hippocampal 5-HT/NA inter-
action is similar to clonidine’s 5-HT/NA action at a2
adrenergic auto-receptors, resulting in enhanced 5-HT
release in hippocampus, an action which was not pro-
duced by diazepam (17).
Another point of view is the relationship between
GABA and the monoamine system. There is a general
agreement that central monoamines are involved in the
etiology of depression (2). Many previous animal studies
reported a complex interaction between GABAergic and
monoaminergic transmissions, especially within the raphe
nuclei which receives in particular GABAergic input (18).
As expected, the GABAergic input onto 5-HT neurons
reduced the firing of these neurons (18). Moreover, the
application of GABA agonists, such as muscimol, in
dorsal and medial raphe nuclei inhibited 5-HT neuronal
release (19). Accordingly, it is possible to speculate that
high basal GABA activity might have led to a reduced
level of serotonergic transmissions in certain brain areas,
which would result in a depressive-like activity, measured
as an increase in the time of immobility in the experi-
ments reported in this research work.
Therefore, it can be concluded that increasing central
GABAergic activity by different mechanisms will result in
a depressant-like activity most likely through the a1
subunit of GABAA receptors.
Fig. 1. Effects of drug treatments on the percentage change in the immobility time in FST. Columns represent Mean9S.E.
Drugs were administered 1 h before the test session and the duration of immobility was measured for 5 min. *PB0.001 as
compared to control group using unpaired Student’s t-test (two samples assuming equal variances) (n6).
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Limitation of this study
This study would have provided more information if
selective an antagonist at the a1 subunit of the GABAA
receptors was included.
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13. Rudolph U, Möhler H. Review GABA-based therapeutic
approaches: GABAA receptor subtype functions. Curr Opin
Pharmacol. 2006; 6: 1823.
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